Literature DB >> 23542365

Development and validation of a cystic fibrosis patient and family member experience of care survey.

Karen Homa1, Kathryn A Sabadosa, Eugene C Nelson, William H Rogers, Bruce C Marshall.   

Abstract

OBJECTIVE: The purpose of this study was to develop a cystic fibrosis (CF)-specific patient and family experience of care survey that CF care centers could use to inform quality improvement efforts.
METHODS: A literature search and query of CF care centers was conducted to identify existing surveys. Individuals with CF, their families, and health care professionals were also asked what to include. Following this process, a draft survey was developed and then reviewed by focus groups. Finally, a version was piloted at 25 CF care centers to validate and further refine the instrument.
RESULTS: No CF-specific surveys were found in the literature. Focus group participants stated that they understood the survey questions and that they covered important aspects of care, particularly infection control. The pilot test of the instrument with 485 participants supported its validity by demonstrating significant differences across centers and that most of the 3 care dimensions had acceptable internal consistency (Cronbach α: adults, 0.71-0.85; children, 0.68-0.79).
CONCLUSION: A CF-specific patient and family experience of care survey was developed with input from individuals with CF, their families, and health care professionals. The instrument was validated and has been deployed to CF care centers.

Entities:  

Mesh:

Year:  2013        PMID: 23542365     DOI: 10.1097/QMH.0b013e31828bc3bc

Source DB:  PubMed          Journal:  Qual Manag Health Care        ISSN: 1063-8628            Impact factor:   0.926


  7 in total

1.  A systematic review of the validity and reliability of patient-reported experience measures.

Authors:  Claudia Bull; Joshua Byrnes; Ruvini Hettiarachchi; Martin Downes
Journal:  Health Serv Res       Date:  2019-06-19       Impact factor: 3.402

2.  Evaluating patient experience in a cystic fibrosis centre using a disease-specific patient satisfaction questionnaire.

Authors:  Helmut Ellemunter; Katja Stahl; Ulrike Smrekar; Gratiana Steinkamp
Journal:  Eur J Pediatr       Date:  2015-05-06       Impact factor: 3.183

3.  Identifying and Integrating Parent Priorities for Psychosocial Support Services in a Pediatric Cystic Fibrosis Clinic.

Authors:  Robin S Everhart; Stephen J Molitor; Dena Wentz; H Joel Schmidt; Michael S Schechter
Journal:  J Clin Psychol Med Settings       Date:  2019-06

4.  Lessons from patient and parent involvement (P&PI) in a quality improvement program in cystic fibrosis care in France.

Authors:  Dominique Pougheon Bertrand; Guy Minguet; Rémi Gagnayre; Pierre Lombrail
Journal:  Orphanet J Rare Dis       Date:  2018-02-08       Impact factor: 4.123

5.  Trans-Atlantic collaboration: applying lessons learned from the US CF Foundation quality improvement initiative.

Authors:  Kathryn A Sabadosa; Marjorie M Godfrey; Bruce C Marshall
Journal:  Orphanet J Rare Dis       Date:  2018-02-08       Impact factor: 4.123

6.  Collaborative research protocol to define patient-reported experience measures of the cystic fibrosis care pathway in France: the ExPaParM study.

Authors:  D Pougheon Bertrand; A Fanchini; P Lombrail; G Rault; A Chansard; N Le Breton; C Frenod; F Milon; C Heymes-Royer; D Segretain; M Silber; S Therouanne; J Haesebaert; C Llerena; P Michel; Q Reynaud
Journal:  Orphanet J Rare Dis       Date:  2022-02-22       Impact factor: 4.123

7.  Explanation and elaboration of the SQUIRE (Standards for Quality Improvement Reporting Excellence) Guidelines, V.2.0: examples of SQUIRE elements in the healthcare improvement literature.

Authors:  Daisy Goodman; Greg Ogrinc; Louise Davies; G Ross Baker; Jane Barnsteiner; Tina C Foster; Kari Gali; Joanne Hilden; Leora Horwitz; Heather C Kaplan; Jerome Leis; John C Matulis; Susan Michie; Rebecca Miltner; Julia Neily; William A Nelson; Matthew Niedner; Brant Oliver; Lori Rutman; Richard Thomson; Johan Thor
Journal:  BMJ Qual Saf       Date:  2016-04-13       Impact factor: 7.035

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.